Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%

Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth

Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India

The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape

Eris Lifesciences consolidates its stake in Swiss Parenterals

The proposed transaction will be effected as a share swap

Eris Lifesciences receives ANVISA approval for sterile injectable facility

Eris Lifesciences receives ANVISA approval at its Ahmedabad campus

Eris Lifesciences appoints Murari Ranganathan to drive cardiometabolic business

Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited

Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr

EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr

Both organisations enter into a long- term collaboration to expand patient access in India

Briefs: Concord Biotech, Cian Healthcare and Eris Lifesciences

Eris Lifesciences enters into term loan agreement with Citi Bank

Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr

Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023